Jan. 15 at 7:06 AM
$ARCT Arcturus Therapeutics, Inc. holds key patents related to the synthesis and structure of high-potency RNA therapeutics, including:
WO2018222890A1 – Filed on May 31, 2018, this patent covers synthetic mRNA constructs with enhanced potency, featuring 5' UTRs derived from plant genes, particularly from the Arabidopsis genus, to improve protein expression in mammalian cells.
US20190002906A1 – A U.S. application that expands on the same technology, describing mRNA constructs for producing therapeutic proteins such as human EPO, Factor IX, alpha-1-antitrypsin, CFTR, and hepcidin.
US Patent 11,015,204 – Granted on May 25, 2021, this issued patent (assigned to Limphong, Pattraranee, et al.) details translatable molecules with increased specific activity and stability, enabling efficient in vivo protein production for therapeutic use.
These patents are foundational to advancing mRNA-based therapies, particularly in treating genetic disorders and protein-deficiency diseases.
